As first-line therapy for advanced renal cell carcinoma, nivolumab plus cabozantinib prolongs progression-free survival compared with sunitinib in patients with and without a prior nephrectomy.
In this small study, even patients with high-risk tumors appeared to benefit from nephron-sparing surgery.
Five-year survival rates following nephrectomy for renal cell carcinoma are higher among patients with favorable vs unfavorable histology.
Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.
New study findings “are critically important in patient counseling and surgical planning, particularly for patients with risk factors for renal deterioration,” according to investigators.
Decisions of how to proceed when positive surgical margins are found after partial nephrectomy are left to the discretion of the surgeon.
Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators.
Systematic review and meta-analysis assessed the impact of delayed surgical intervention on localized and metastatic renal cell carcinoma.
A study of the effect of renal hypothermia during partial nephrectomy should have an immediate impact on surgical practice, according to investigators.
Study findings corroborate previous research linking higher income with increased healthcare utilization.
